Ridaforolimus: Phase I data

In an open-label Phase I trial in 62 patients with advanced solid tumors, ridaforolimus plus dalotuzumab produced 3 confirmed partial responses, 2 partial metabolic responses and 2 cases of stable disease for >6 months. The MTD was 40 mg/day ridaforolimus plus 10 mg/kg/week dalotuzumab. Patients received oral ridaforolimus at escalating doses of 10-40 mg/day for 5 weeks in combination with IV dalotuzumab dosed at 10 mg/kg/week or 7.5 mg/kg every other week. ...